SCHEMBL4487942

SCHEMBL4487942

NC(=O)C1CCN(CCC(=O)Nc2cccc(C(=O)NCCN3CCC(OC(=O)N(c4ccccc4-c4ccccc4)N(C(=O)O)c4ccccc4-c4ccccc4)CC3)c2)CC1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.49
ALDH1A1 P00352 5/20 0.47
POLB P06746 2/20 0.47
TP53 P04637 1/20 0.43
EPHX2 P34913 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CHRM2 P08172 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
KDM4E B2RXH2 2/20 0.41
LMNA P02545 1/20 0.41
MAPK1 P28482 1/20 0.41
HIF1A Q16665 1/20 0.41
ATR Q13535 2/20 0.39
CHRM3 P20309 2/20 0.39
ADRB2 P07550 1/20 0.39
KMT2A Q03164 1/20 0.38
HSD17B10 Q99714 2/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4477850 0.94 ALDH1A1 (0.48) NPSR1ALDH1A1POLBTP53EPHX2
SCHEMBL4470548 0.93 ATR (0.44) ALDH1A1POLBEPHX2SMN1; SMN2LMNA
SCHEMBL4480181 0.89 CARM1 (0.47) EPHX2CHRM3
SCHEMBL4472540 0.89 EPHX2 (0.43) EPHX2ATRCHRM3ADRB2
SCHEMBL4490817 0.88 CHRM3 (0.41) NPSR1EPHX2CHRM3ADRB2
SCHEMBL4470442 0.88 CARM1 (0.46) EPHX2CHRM3
SCHEMBL4482354 0.88 EPHX2 (0.41) ALDH1A1EPHX2CHRM2KDM4EATR
SCHEMBL4480375 0.87 EPHX2 (0.44) EPHX2ATRCHRM3
SCHEMBL4486948 0.87 EPHX2 (0.44) ALDH1A1POLBEPHX2SMN1; SMN2LMNA
SCHEMBL4494143 0.87 EPHX2 (0.44) EPHX2ATRCHRM3ADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7632847-B2 Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-(2-(3-[3-(4-hydroxybenzylamino)propionylamino]benzoylamino)ethyl)piperidin-4-yl ester THERAVANCE, INC. (US) 2009-12-15 US disclosed